Research and Markets: H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bgd2x3/h5n1_infection) has announced the addition of Global Markets Direct's new report "H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2012" to their offering.

“H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2012”

This report provides information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza). H5N1 Infection (Avian Influenza) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for H5N1 Infection (Avian Influenza).

- A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Involved in H5N1 Infection (Avian Influenza) Therapeutics Development

- Baxter International Inc.

- Sanofi-Aventis

- GlaxoSmithKline plc

- Inovio Biomedical Corporation

- Emergent BioSolutions Inc.

- Generex Biotechnology Corporation

- Nanotherapeutics, Inc.

- Archimedes Pharma Limited

- Novartis AG

- MDRNA, Inc.

- Novavax, Inc.

- CEL-SCI Corporation

- Crucell N.V.

- OPKO Health, Inc.

- Hemispherx Biopharma, Inc.

- Intercell AG

- Medicago Inc.

- NanoViricides, Inc.

- CytoGenix, Inc.

- XOMA Ltd.

- Green Cross Corporation

- Antigen Express, Inc.

- Colby Pharmaceutical Company

- LigoCyte Pharmaceuticals, Inc.

- Adimmune Corporation

- TechnoVax, Inc.

- MacroGenics, Inc.

- AlphaVax, Inc.

- Vaxin, Inc.

- Theraclone Sciences, Inc.

- REPLICor Inc.

- Protein Sciences Corporation

- VaxInnate Corporation

- Obio Pharmaceutical Holdings Limited.

- Canopus BioPharma Incorporated

- iBio, Inc.

- Sirnaomics, Inc.

- Alios BioPharma, Inc.

- Vaxart, Inc.

- NasVax Ltd.

- The National Institute of Allergy and Infectious Diseases

- ImmuneRegen BioSciences, Inc.

- Inviragen, Inc.

- PaxVax

- Denka Seiken Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/bgd2x3/h5n1_infection

Source: Global Markets Direct